Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nesrin Mogulkoc

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|December 10, 2024
Lung cancer in patients with pulmonary fibrosis: characteristics features and prognosisSibel Kara, Nesrin Mogulkoc, Gamze Kirkil, et al.
European Radiology|July 28, 2023
Automated airway quantification associates with mortality in idiopathic pulmonary fibrosisWing Keung Cheung, Ashkan Pakzad, Nesrin Mogulkoc, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b studySteven D Nathan, Jürgen Behr, Harold R Collard, et al.
The European Respiratory Journal|February 4, 2022
Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosisTim J M Wallis, Eyjólfur Gudmundsson, Katarina Pontoppidan, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 27, 2021
Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?Meena Kalluri, Fabrizio Luppi, Ada Vancheri, et al.
Annals of Thoracic Medicine|April 16, 2025
Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosisNesrin Ocal, Aykut Cilli, Nesrin Mogulkoc, et al.
Journal of Big Data|August 7, 2024
Interpolation-split: a data-centric deep learning approach with big interpolated data to boost airway segmentation performanceWing Keung Cheung, Ashkan Pakzad, Nesrin Mogulkoc, et al.
ERJ Open Research|February 3, 2021
The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensusArgyris Tzouvelekis, Katerina Antoniou, Michael Kreuter, et al.
The European Respiratory Journal|March 12, 2026
Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 studyBernt Van Den Blink, Surinder S Birring, Nesrin Mogulkoc, et al.
American Journal of Respiratory and Critical Care Medicine|March 14, 2024
Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary FibrosisWaldo L L D Mattos, Nasreen Khalil, Lisa G Spencer, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|December 10, 2024
Lung cancer in patients with pulmonary fibrosis: characteristics features and prognosisSibel Kara, Nesrin Mogulkoc, Gamze Kirkil, et al.
European Radiology|July 28, 2023
Automated airway quantification associates with mortality in idiopathic pulmonary fibrosisWing Keung Cheung, Ashkan Pakzad, Nesrin Mogulkoc, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b studySteven D Nathan, Jürgen Behr, Harold R Collard, et al.
The European Respiratory Journal|February 4, 2022
Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosisTim J M Wallis, Eyjólfur Gudmundsson, Katarina Pontoppidan, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 27, 2021
Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?Meena Kalluri, Fabrizio Luppi, Ada Vancheri, et al.
Annals of Thoracic Medicine|April 16, 2025
Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosisNesrin Ocal, Aykut Cilli, Nesrin Mogulkoc, et al.
Journal of Big Data|August 7, 2024
Interpolation-split: a data-centric deep learning approach with big interpolated data to boost airway segmentation performanceWing Keung Cheung, Ashkan Pakzad, Nesrin Mogulkoc, et al.
ERJ Open Research|February 3, 2021
The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensusArgyris Tzouvelekis, Katerina Antoniou, Michael Kreuter, et al.
The European Respiratory Journal|March 12, 2026
Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 studyBernt Van Den Blink, Surinder S Birring, Nesrin Mogulkoc, et al.
American Journal of Respiratory and Critical Care Medicine|March 14, 2024
Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary FibrosisWaldo L L D Mattos, Nasreen Khalil, Lisa G Spencer, et al.
Pageof 6